During the CROWN trial, lorlatinib was shown to be associated with longer progression-free survival and a higher frequency of intracranial response to brain metastasis when compared to crizotinib—the first-line agent used for advanced ALK-positive NSCLC [4]. Here, ALK is linked to non-small cell lung carcinoma.